The immunotherapy of lung cancer

doi:10.3760/cma.j.issn.1673-422X.2015.10.016

Abstract

Abstract: Lung cancer is characterized by high malignancy and the majority of patients are diagnosed at the advanced or late stage. Chemoradiotherapy has insufficient effect on this malignant tumor. At present the immune therapy has become a new choice for lung cancer treatment. Ipilimumab, antibody to programmed death1, immune cells, cytokines, melanomaassociated antigen A3 vaccine, liposomal BLP25, belagenpumatucelL and polypeptide vaccine have been proved effective for lung cancer through various clinical trials. Futhermore, most of them have been moved forward to phase Ⅲ clinical trials in order to get more strong evidence to support the immunotherapy incorporated into the multidisciplinary treatment of lung cancer.

Key words: Lung neoplasms, Immunity, passive, Antibody, monoclonal

Zhang Shujuan, Chang Jianhua. The immunotherapy of lung cancer[J]. Journal of International Oncology, 2015, 42(10): 776-779.

References

［1］ Jemal A, Siegel R, Xu J , et al. Cancer statistics, 2010［J］. CA Cancer J Clin, 2010, 60(5): 277-300. ［2］ Crinò L, Weder W, van Meerbeeck J, et al. Early stage and locally advanced (nonmetastatic) nonsmallcell lung cancer: ESMO clinical practice guidelines for diagnosis， treatment and followup［J］. Ann Oncol, 2010, 21 Suppl 5: v103-v115. ［3］ Tucker ZC, Laguna BA, Moon E, et al. Adjuvant immunotherapy for non-small cell lung cancer［J］. Cancer Treat Rev, 2012, 38 (6): 650-661. ［4］ Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age［J］. Nature, 2011, 480(7378): 480-489. ［5］ Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as firstline treatment in stage ⅢB/Ⅳ nonsmall cell lung cancer: results from a randomized, doubleblind, multicenter phase Ⅱ study ［J］. J Clin Oncol, 2012, 30(17): 2046-2054. ［6］ Garon EB, Balmanoukian A, Hamid O, et al. MK3475 monotherapy for previously treated nonsmall cell lung cancer (NSCLC): preliminary safety and clinical activity［J］. Clin Cancer Res, 2014, 20(Suppl 2): A20. ［7］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 2443-2454. ［8］ Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in advanced squamouscell nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(2): 123-135. ［9］ Li R, Wang C, Liu L, et al. Autologous cytokineinduced killer cell immunotherapy in lung cancer: a phase Ⅱ clinical study［J］. Cancer Immunol Immunother, 2012, 61(11): 2125-2133. ［10］ Kilic A, Landreneau RJ, Luketich JD, et al. Density of tumorinfiltrating lymphocytes correlates with disease recurrence and survival in patients with large nonsmallcell lung cancer tumors［J］. J Surg Res, 2011, 167(2): 207-210. ［11］ Liu H, Zhang T, Ye J, et al. Tumorinfiltrating lymphocytes predict response to chemotherapy in patients with advance nonsmall cell lung cancer［J］. Cancer Immunol Immunother, 2012, 61(10): 1849-1856. ［12］ Iwai K, Soejima K, Kudoh S, et al. Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study［J］. Cancer Immunol Immunother, 2012, 61(10): 1781-1790. ［13］ Liu JF, Liu F, Qi YC, et al. Studies on IFNgamma mediated reversion of CIK killing sensitivity to edited human lung cancer A549 cells［J］. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2010, 26(4): 354-355, 358. ［14］ Ridolfi L, Bertetto O, Santo A, et al. Chemotherapy with or without lowdose interleukin2 in advanced nonsmall cell lung cancer: results from a phase Ⅲ randomized multicentric trial［J］. Int J Oncol, 2011, 39(4): 1011-1017. ［15］ Ratto GB, Costa R, Maineri P, et al. Neoadjuvant chemo/immunotherapy in the treatment of stage Ⅲ (N2) nonsmall cell lung cancer: a phase Ⅰ/Ⅱ pilot study［J］. Int J Immunopathol Pharmacol, 2011, 24(4): 1005-1016. ［16］ Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage ⅢB or Ⅳ non-small-cell lung cancer receiving BLP25 liposome vaccine (LBLP25): phase ⅡB randomized, multicenter, openlabel trial ［J］. J Cancer Res Clin Oncol, 2011, 137(9): 1337-1342. ［17］ Thomas A, Hassan R. Immunotherapies for nonsmallcell lung cancer and mesothelioma［J］. Lancet Oncol, 2012, 13(7): e301-e310. ［18］ Nemunaitis J, Nemunaitis M, Senzer N, et al. Phase Ⅱ trial of belagenpumatucelL, a TGFbeta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther, 2009, 16(8): 620-624.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[3]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[4]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[5]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[6]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[7]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[8]	Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301.
[9]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251.
[10]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[11]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 111-115.
[12]	Huang Huayu, Song Qibin, Gong Hongyun, Song Jia. Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy [J]. Journal of International Oncology, 2022, 49(12): 718-723.
[13]	Zhang Hongjiao, Jiang Jie, Huang Wei. Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis [J]. Journal of International Oncology, 2022, 49(1): 51-55.
[14]	Hu Ge, Su Jie, Li Qiangwei, Xu Peng, Xu Xiuli, Qian Xiaotao. Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer [J]. Journal of International Oncology, 2021, 48(9): 523-526.
[15]	Wang Jun, Zhao Xia, Li Haifei, Zhang Cheng. Clinic diagnostic value of MSCT imaging features in nodular lung adenocarcinoma subtype [J]. Journal of International Oncology, 2021, 48(9): 537-543.